ADCs based on anti-CDH17 antibodies linked to MMAE showed potent anti-tumor activity in xenograft models of PDAC and CRC.561,562 Other targets that showed significant tumor response in preclinical models when targeted by ADCs include GPR56 in CRC or GPC-1 in pancreatic cancer.563,564 Whether these ADCs can confirm their efficacy in clinical trials is an open question. This evidence concerns the gene ADGRG1 and pancreatic neoplasm.